Tesamorelin (12mg) + Ipamorelin (3mg) Blend

This research blend combines Tesamorelin (a stabilized GHRH analog with trans-3-hexenoic acid modification) with Ipamorelin (the most selective growth hormone secretagogue), enabling simultaneous activation of both the GHRH receptor and ghrelin receptor (GHS-R1a) pathways. This dual-receptor approach leverages Tesamorelin's enhanced stability and potency with Ipamorelin's exceptional selectivity profile. This blend is utilized in laboratory research to study optimized growth hormone release through complementary pathway activation. All discussion herein is limited to experimental research contexts and does not imply applied, therapeutic, or physiological use.

This Tesamorelin/Ipamorelin blend is employed in laboratory research to study optimized GH secretion through dual receptor activation with enhanced stability. Common experimental applications include GH pulse analysis, pituitary function studies, metabolic pathway investigations, and body composition research. Research protocols utilize this combination to investigate whether combining a stabilized GHRH analog with a selective GHS provides advantages for sustained GH release amplitude and metabolic effects over single-pathway approaches.

Mechanistically, this blend engages two complementary pathways with distinct advantages. Tesamorelin activates GHRH receptors on pituitary somatotrophs with enhanced stability due to its trans-3-hexenoic acid modification, promoting sustained GH gene transcription and priming cells for secretion. Simultaneously, Ipamorelin activates GHS-R1a receptors, which amplify the GH release triggered by GHRH. The synergy arises because GHRH and GHS pathways utilize different intracellular signaling cascades (cAMP vs. calcium/PKC) that converge on GH secretion. Tesamorelin's extended activity combined with Ipamorelin's selective amplification produces robust, sustained GH release while maintaining physiological pulsatility and a clean hormonal profile.

Preclinical investigations of Tesamorelin/Ipamorelin combinations include in-vitro pituitary cell studies and in-vivo animal models evaluating GH secretion dynamics and metabolic effects. Reported findings include synergistic GH release, sustained pulsatile patterns, elevated IGF-1 levels, and improvements in body composition markers without significant cortisol or prolactin changes. Animal studies explore the advantages of combining a stabilized GHRH analog with a selective GHS over single peptide approaches for growth hormone axis research and metabolic applications. All findings are interpreted strictly within the context of laboratory research models.